
    
      This is a Phase II, prospective, placebo-controlled, double-blinded (investigator/site staff
      and participants), multi-center, multi-regional study; the Sponsor will be blinded until the
      interim analysis. Participants who are generally healthy or with stable pre-existing health
      conditions will be randomized, stratified by age (≥ 20 to < 65 years and ≥ 65 years of
      age).All eligible participants will be randomized to receive 2 doses of either MVC-COV1901 or
      placebo in a predefined ratio.
    
  